HLB announced that the clinical results of
the Rivoceranib (Apatinib) study conducted in China confirmed several
significant results, including complete remission in hepatocellular carcinoma. In
addition, complete remission is observed for gastric cancer, lung cancer,
esophageal cancer, and T-cell lymphoma, and the efficacy of Rivoceranib against
various carcinomas is once again attracting attention.
A retrospective clinical trial in which
Rivoceranib and Camrelizumab (PD-1 antibody) were administered in combination
in 63 patients with advanced hepatocellular carcinoma at five hospitals
including Nanfang Hospital of Southern Medical University, Shunde Hospital, and
The First Affiliated Hospital of Sun Yat-sen University.
As a result, one complete remission case
was observed, with 44% of Overall Response Rate (ORR), 75% of Disease Control
Rate (DCR), 11.8 months of Progressive-Free Survival (mPFS), and 14.8 months of
Overall Survival (mOS). In particular, the company explained that the clinical
trial was very encouraging in that it was conducted on patients with Portal
Bean Tumor Thrombus, which is known to be fast in progress and spread.
A HLB official said, "There are
currently more than 300 clinical trials on Rivoceranib, including research
clinical trials, and complete remission of various cancerous species is being
observed one after another." And added, "In particular, high drug
efficacy has been confirmed in the combination therapy of Rivoceranib and Camrelizumab,
which is the same primary treatment for liver cell cancer that the company is
focusing on."
HLB is currently conducting the third phase
of global clinical trials in Korea, China, the United States, Europe, and
Taiwan for a total of 510 people for the purpose of primary treatment of hepatocellular
carcinoma. As of August, the recruitment rate of patients exceeded 50%.